<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using EDGARfilings PROfile 6.5.1.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">As filed with the Securities and Exchange Commission on March 10, 2020</div>
    <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Registration No. 333-</div>
    <div>
      <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center"></div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">UNITED STATES</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 18pt; font-weight: bold;">FORM S-8</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">REGISTRATION STATEMENT</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-style: italic; font-weight: bold;">UNDER</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-style: italic; font-weight: bold;">THE SECURITIES ACT OF 1933</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 24pt; font-weight: bold;">Bionano Genomics, Inc.</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">(Exact name of registrant as specified in its charter)</div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zfa1f1c2a213a4f2ab700a836bc3250e7" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 51.12%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Delaware</div>
          </td>
          <td style="width: 48.88%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">26-1756290</div>
          </td>
        </tr>
        <tr>
          <td style="width: 51.12%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">(State or other jurisdiction of</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">incorporation or organization)</div>
          </td>
          <td style="width: 48.88%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">(I.R.S. Employer</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Identification No.)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 51.12%; vertical-align: middle;">&#160;</td>
          <td style="width: 48.88%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 51.12%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">9540 Towne Centre Drive, Suite 100</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">San Diego, California</div>
          </td>
          <td style="width: 48.88%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">92121</div>
          </td>
        </tr>
        <tr>
          <td style="width: 51.12%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">(Address of Principal Executive Offices)</div>
          </td>
          <td style="width: 48.88%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">(Zip Code)</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Bionano Genomics, Inc. Amended and Restated 2018 Equity Incentive Plan</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Bionano Genomics, Inc. 2018 Employee Stock Purchase Plan</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">(Full titles of the plans)</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">R. Erik Holmlin, Ph.D.</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">President and Chief Executive Officer</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Bionano Genomics, Inc.</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">9540 Towne Centre Drive, Suite 100</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">San Diego, California 92121</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">(858) 888-7600</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">(Name, address, including zip code, and telephone number, including area code, of agent for service)</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-style: italic; font-weight: bold;">Copies to:</div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zd575d373ed4241dd8897251c74339ebd" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 51.12%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Thomas A. Coll, Esq.</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">James C. Pennington, Esq.</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Cooley LLP</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">4401 Eastgate Mall</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">San Diego, California 92121</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">(858) 550-6000</div>
          </td>
          <td style="width: 48.88%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">R. Erik Holmlin, Ph.D.</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">President and Chief Executive Officer</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Bionano Genomics, Inc.</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">9540 Towne Centre Drive, Suite 100</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">San Diego, California 92121</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">(858) 888-7600</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the
      definitions of &#8220;large accelerated filer,&#8221;&#160;&#8220;accelerated filer,&#8221;&#160;&#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z8e45de934bde4b8fb8f4ed38665b658b" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 43.04%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Large accelerated filer</div>
          </td>
          <td style="width: 6.96%; vertical-align: top;">
            <div style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</div>
          </td>
          <td style="width: 43.04%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Accelerated filer</div>
          </td>
          <td style="width: 6.96%; vertical-align: top;">
            <div style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 43.04%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Non-accelerated filer</div>
          </td>
          <td style="width: 6.96%; vertical-align: top;">
            <div style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</div>
          </td>
          <td style="width: 43.04%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Smaller reporting company</div>
          </td>
          <td style="width: 6.96%; vertical-align: top;">
            <div style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 43.04%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Emerging growth company</div>
          </td>
          <td style="width: 6.96%; vertical-align: top;">
            <div style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</div>
          </td>
          <td style="width: 43.04%; vertical-align: top;">&#160;</td>
          <td style="width: 6.96%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman', Times, serif;">If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
      standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">CALCULATION OF REGISTRATION FEE</div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z87b43b27551e4a288cb350c90841ad10" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 46.22%; vertical-align: bottom; border-top: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Title of Securities</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">to be Registered</div>
          </td>
          <td style="width: 13.44%; vertical-align: bottom; border-top: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Amount</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">to be</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Registered<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div>
          </td>
          <td style="width: 13.44%; vertical-align: bottom; border-top: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Proposed</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Maximum</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Offering Price</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Per Share<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div>
          </td>
          <td style="width: 13.44%; vertical-align: bottom; border-top: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Proposed</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Maximum</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Aggregate</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Offering Price<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div>
          </td>
          <td style="width: 13.46%; vertical-align: bottom; border-top: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Amount of</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Registration Fee</div>
          </td>
        </tr>
        <tr>
          <td style="width: 46.22%; vertical-align: top; border-top: #000000 2px solid;">
            <div style="text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">2018 Equity Incentive Plan</div>
            <div style="font-family: 'Times New Roman', Times, serif;">Common Stock, $0.0001 par value per share</div>
          </td>
          <td style="width: 13.44%; vertical-align: bottom; border-top: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">1,713,723<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></div>
          </td>
          <td style="width: 13.44%; vertical-align: bottom; border-top: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">$0.75</div>
          </td>
          <td style="width: 13.44%; vertical-align: bottom; border-top: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">$1,285,293</div>
          </td>
          <td style="width: 13.46%; vertical-align: bottom; border-top: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">$167</div>
          </td>
        </tr>
        <tr>
          <td style="width: 46.22%; vertical-align: top; border-top: #000000 2px solid;">
            <div style="text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">2018 Employee Stock Purchase Plan</div>
            <div style="text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif;">Common Stock, $0.0001 par value per share</div>
          </td>
          <td style="width: 13.44%; vertical-align: bottom; border-top: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">220,000<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup></div>
          </td>
          <td style="width: 13.44%; vertical-align: bottom; border-top: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">$0.75</div>
          </td>
          <td style="width: 13.44%; vertical-align: bottom; border-top: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">$165,000</div>
          </td>
          <td style="width: 13.46%; vertical-align: bottom; border-top: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">$22</div>
          </td>
        </tr>
        <tr>
          <td style="width: 46.22%; vertical-align: top; border-top: #000000 2px solid;">
            <div style="text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Total</div>
          </td>
          <td style="width: 13.44%; vertical-align: bottom; border-top: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">1,933,723</div>
          </td>
          <td style="width: 13.44%; vertical-align: bottom; border-top: #000000 2px solid;">&#160;</td>
          <td style="width: 13.44%; vertical-align: bottom; border-top: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">$1,450,293</div>
          </td>
          <td style="width: 13.46%; vertical-align: bottom; border-top: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">$189</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zb3ff7562eb5941d68502f1d5fb11ab60" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 3.5%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(1)</div>
          </td>
          <td colspan="3" style="width: 96.5%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the &#8220;<font style="font-weight: bold; font-style: italic;">Securities Act</font>&#8221;), this Registration Statement
              shall also cover any additional shares of Common Stock (&#8220;<font style="font-weight: bold; font-style: italic;">Common Stock</font>&#8221;) of Bionano Genomics, Inc. (the &#8220;<font style="font-weight: bold; font-style: italic;">Registrant</font>&#8221;) that
              become issuable under the Registrant&#8217;s 2018 Equity Incentive Plan (the &#8220;<font style="font-weight: bold; font-style: italic;">2018 Plan</font>&#8221;) or the Registrant&#8217;s 2018 Employee Stock Purchase Plan (the &#8220;<font style="font-weight: bold; font-style: italic;">2018 ESPP</font>&#8221;) by reason of any stock dividend, stock split, recapitalization or other similar transaction.</div>
          </td>
        </tr>
        <tr>
          <td colspan="3" style="width: 3.64%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(2)</div>
          </td>
          <td style="width: 96.36%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">This estimate is made pursuant to Rule 457(h)(1) and Rule 457(c) of the Securities Act solely for purposes of calculating the registration fee. The price per share and aggregate
              offering price are based upon the average of the high and low prices of the Common Stock on March 9, 2020, as reported on the Nasdaq Capital Market.</div>
          </td>
        </tr>
        <tr>
          <td colspan="2" style="width: 3.56%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(3)</div>
          </td>
          <td colspan="2" style="width: 96.44%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Represents shares of Common Stock that were automatically added to the shares authorized for issuance under the 2018 Plan on January 1, 2020 pursuant to an &#8220;evergreen&#8221; provision
              contained in the 2018 Plan. Pursuant to such provision, on January 1<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup> of each year through January 1, 2028, the number of shares authorized for issuance under
              the 2018 Plan will be automatically increased by the lesser of: (a) 5% of the total number of shares of capital stock of the Registrant outstanding on December 31 of the preceding calendar year; or (b) such lesser number of shares of Common
              Stock as the Registrant&#8217;s board of directors (the &#8220;<font style="font-weight: bold; font-style: italic;">Board</font>&#8221;) may designate prior to the applicable January 1<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup>.</div>
          </td>
        </tr>
        <tr>
          <td colspan="2" style="width: 3.56%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(4)</div>
          </td>
          <td colspan="2" style="width: 96.44%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Represents shares of Common Stock that were automatically added to the shares authorized for issuance under the 2018 ESPP on January 1, 2020 pursuant to an &#8220;evergreen&#8221; provision
              contained in the 2018 ESPP. Pursuant to such provision, on January 1<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup> of each year through January 1, 2028, the number of shares authorized for issuance under
              the 2018 ESPP will be automatically increased by a number equal to the lesser of: (a) 1% of the total number of shares of capital stock outstanding on December 31 of the preceding calendar year; (b) 220,000 shares; or (c) such lesser number
              of shares of Common Stock as the Board may designate prior to the applicable January 1<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup>.</div>
          </td>
        </tr>

    </table>
    <div>
      <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center"></div>
    <div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageFooter"></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">INCORPORATION OF DOCUMENTS BY REFERENCE</div>
      <div><br>
      </div>
      <div style="font-family: 'Times New Roman', Times, serif;">This Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement of the Registrant on
        Form S-8 relating to the same employee benefit plan is effective.</div>
      <div><br>
      </div>
      <div style="font-family: 'Times New Roman', Times, serif;">The Registrant previously registered shares of its Common Stock for issuance under the 2018 Plan and 2018 ESPP under Registration Statements on Form S-8 filed with the Securities and Exchange
        Commission (the &#8220;<font style="font-weight: bold; font-style: italic;">Commission</font>&#8221;) on <a href="http://www.sec.gov/Archives/edgar/data/1411690/000119312518260602/d616702ds8.htm">August 28, 2018 (File No. 333-227073)</a> and <a href="http://www.sec.gov/Archives/edgar/data/1411690/000119312519091060/d626460ds8.htm">March 28, 2019 (File No. 333-230589)</a>. Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the
        contents of the Registration Statements referenced above.</div>
      <div><br>
      </div>
      <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">ITEM 8. EXHIBITS.</div>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z8426051be52c4adcb901c070d5cfbee8" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 10.4%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">Exhibit </div>
              <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">Number</div>
            </td>
            <td style="width: 89.6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Description</div>
            </td>
          </tr>
          <tr>
            <td style="width: 10.4%; vertical-align: top; background-color: rgb(255, 255, 255);">
              <div style="font-family: 'Times New Roman', Times, serif;"><a href="http://www.sec.gov/Archives/edgar/data/1411690/000119312518257763/d607608dex31.htm">4.1<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></a></div>
            </td>
            <td style="width: 89.6%; vertical-align: top; background-color: rgb(255, 255, 255);">
              <div style="font-family: 'Times New Roman', Times, serif;">Amended and Restated Certificate of Incorporation of the Registrant.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 10.4%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="font-family: 'Times New Roman', Times, serif;"><a href="http://www.sec.gov/Archives/edgar/data/1411690/000119312518257763/d607608dex32.htm">4.2<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></a></div>
            </td>
            <td style="width: 89.6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="font-family: 'Times New Roman', Times, serif;">Amended and Restated Bylaws of the Registrant.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 10.4%; vertical-align: top; background-color: rgb(255, 255, 255);">
              <div style="font-family: 'Times New Roman', Times, serif;"><a href="http://www.sec.gov/Archives/edgar/data/0001411690/000119312518219135/d782664dex41.htm">4.3<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></a></div>
            </td>
            <td style="width: 89.6%; vertical-align: top; background-color: rgb(255, 255, 255);">
              <div style="font-family: 'Times New Roman', Times, serif;">Form of Common Stock Certificate of the Registrant.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 10.4%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="font-family: 'Times New Roman', Times, serif;"><a href="nt10009730x2_ex5-1.htm">5.1</a></div>
            </td>
            <td style="width: 89.6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="font-family: 'Times New Roman', Times, serif;">Opinion of Cooley LLP.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 10.4%; vertical-align: top; background-color: rgb(255, 255, 255);">
              <div style="font-family: 'Times New Roman', Times, serif;"><a href="nt10009730x2_ex23-1.htm">23.1</a></div>
            </td>
            <td style="width: 89.6%; vertical-align: top; background-color: rgb(255, 255, 255);">
              <div style="font-family: 'Times New Roman', Times, serif;">Consent of Independent Registered Public Accounting Firm.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 10.4%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="font-family: 'Times New Roman', Times, serif;"><a href="nt10009730x2_ex5-1.htm">23.2</a></div>
            </td>
            <td style="width: 89.6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="font-family: 'Times New Roman', Times, serif;">Consent of Cooley LLP. Reference is made to Exhibit 5.1.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 10.4%; vertical-align: top; background-color: rgb(255, 255, 255);">
              <div style="font-family: 'Times New Roman', Times, serif;"><a href="#SIGN">24.1</a></div>
            </td>
            <td style="width: 89.6%; vertical-align: top; background-color: rgb(255, 255, 255);">
              <div style="font-family: 'Times New Roman', Times, serif;">Power of Attorney. Reference is made to the signature page hereto.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 10.4%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="font-family: 'Times New Roman', Times, serif;"><a href="http://www.sec.gov/Archives/edgar/data/1411690/000119312518260602/d616702dex993.htm">99.1<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></a></div>
            </td>
            <td style="width: 89.6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="font-family: 'Times New Roman', Times, serif;">Bionano Genomics, Inc. 2018 Equity Incentive Plan.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 10.4%; vertical-align: top; background-color: rgb(255, 255, 255);">
              <div style="font-family: 'Times New Roman', Times, serif;"><a href="http://www.sec.gov/Archives/edgar/data/1411690/000119312518219135/d782664dex105.htm">99.2<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></a></div>
            </td>
            <td style="width: 89.6%; vertical-align: top; background-color: rgb(255, 255, 255);">
              <div style="font-family: 'Times New Roman', Times, serif;">Forms of Stock Option Grant Notice, Option Agreement and Notice of Exercise under the 2018 Plan.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 10.4%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="font-family: 'Times New Roman', Times, serif;"><a href="http://www.sec.gov/Archives/edgar/data/1411690/000119312518260602/d616702dex995.htm">99.3<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></a></div>
            </td>
            <td style="width: 89.6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="font-family: 'Times New Roman', Times, serif;">Bionano Genomics, Inc. 2018 Employee Stock Purchase Plan.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zdd4cbc334fae4fb29805a582e314d113" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 3.54%; vertical-align: top;">
              <div style="font-family: 'Times New Roman', Times, serif;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div>
            </td>
            <td style="width: 96.46%; vertical-align: top;">
              <div style="font-family: 'Times New Roman', Times, serif;">Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on August 24, 2018.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3.54%; vertical-align: top;">
              <div style="font-family: 'Times New Roman', Times, serif;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div>
            </td>
            <td style="width: 96.46%; vertical-align: top;">
              <div style="font-family: 'Times New Roman', Times, serif;">Incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-225970), as amended.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3.54%; vertical-align: top;">
              <div style="font-family: 'Times New Roman', Times, serif;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></div>
            </td>
            <td style="width: 96.46%; vertical-align: top;">
              <div style="font-family: 'Times New Roman', Times, serif;">Incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-8 (File No. 333-227073).</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter"></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
        <div id="DSPFPageHeader"></div>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><a name="SIGN"><!--Anchor--></a>SIGNATURES</div>
      <div><br>
      </div>
      <div style="font-family: 'Times New Roman', Times, serif;">Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on
        Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on March 10, 2020.</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zca34bf4b84484b388a5fe9fa88f467e8" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 6%; vertical-align: middle;">&#160;</td>
            <td style="width: 44%; vertical-align: bottom;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td colspan="2" style="vertical-align: top;">
              <div style="text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">BIONANO GENOMICS, INC.</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: middle;">&#160;</td>
            <td style="width: 44%; vertical-align: middle;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif;">By:</div>
            </td>
            <td style="width: 44%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif;">/s/ R. Erik Holmlin, Ph.D.</div>
            </td>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top;">&#160;</td>
            <td style="width: 44%; vertical-align: bottom;">
              <div style="text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif;">R. Erik Holmlin, Ph.D.</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top;">&#160;</td>
            <td style="width: 44%; vertical-align: bottom;">
              <div style="text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">President and Chief Executive Officer</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
      <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">POWER OF ATTORNEY</div>
      <div><br>
      </div>
      <div style="font-family: 'Times New Roman', Times, serif;">KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints R. Erik Holmlin, Ph.D. as his or her true and lawful attorney-in-fact and agent, with the
        full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with exhibits
        thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be
        done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to
        be done by virtue hereof.</div>
      <div><br>
      </div>
      <div style="font-family: 'Times New Roman', Times, serif;">Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.</div>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zed8ababab3704adabd61c6bb52fc65a8" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 33%; vertical-align: bottom;">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Signature</div>
            </td>
            <td style="width: 34%; vertical-align: bottom;">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Title</div>
            </td>
            <td style="width: 33%; vertical-align: bottom;">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Date</div>
            </td>
          </tr>
          <tr>
            <td style="width: 33%; vertical-align: top;">&#160;</td>
            <td style="width: 34%; vertical-align: top;">&#160;</td>
            <td style="width: 33%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">/s/ R. Erik Holmlin, Ph.D.</div>
            </td>
            <td style="width: 34%; vertical-align: top;">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">Chief Executive Officer and Director</div>
            </td>
            <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">March 10, 2020</div>
            </td>
          </tr>
          <tr>
            <td style="width: 33%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">R. Erik Holmlin, Ph.D.</div>
            </td>
            <td style="width: 34%; vertical-align: top;">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-style: italic;">(Principal Executive and Financial Officer)</div>
            </td>
            <td style="width: 33%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 33%; vertical-align: top;">&#160;</td>
            <td style="width: 34%; vertical-align: top;">&#160;</td>
            <td style="width: 33%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">/s/ Mark Adamchak</div>
            </td>
            <td style="width: 34%; vertical-align: top;">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">Controller</div>
            </td>
            <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">March 10, 2020</div>
            </td>
          </tr>
          <tr>
            <td style="width: 33%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">Mark Adamchak</div>
            </td>
            <td style="width: 34%; vertical-align: top;">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-style: italic;">(Principal Accounting Officer)</div>
            </td>
            <td style="width: 33%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 33%; vertical-align: top;">&#160;</td>
            <td style="width: 34%; vertical-align: top;">&#160;</td>
            <td style="width: 33%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">/s/ David L. Barker, Ph.D.</div>
            </td>
            <td style="width: 34%; vertical-align: top;">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">Director</div>
            </td>
            <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">March 10, 2020</div>
            </td>
          </tr>
          <tr>
            <td style="width: 33%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">David L. Barker, Ph.D.</div>
            </td>
            <td style="width: 34%; vertical-align: top;">&#160;</td>
            <td style="width: 33%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 33%; vertical-align: top;">&#160;</td>
            <td style="width: 34%; vertical-align: top;">&#160;</td>
            <td style="width: 33%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">/s/ Albert A. Luderer, Ph.D.</div>
            </td>
            <td style="width: 34%; vertical-align: top;">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">Director</div>
            </td>
            <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">March 10, 2020</div>
            </td>
          </tr>
          <tr>
            <td style="width: 33%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">Albert A. Luderer, Ph.D.</div>
            </td>
            <td style="width: 34%; vertical-align: top;">&#160;</td>
            <td style="width: 33%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 33%; vertical-align: top;">&#160;</td>
            <td style="width: 34%; vertical-align: top;">&#160;</td>
            <td style="width: 33%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">/s/ Junfeng Wang</div>
            </td>
            <td style="width: 34%; vertical-align: top;">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">Director</div>
            </td>
            <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">March 10, 2020</div>
            </td>
          </tr>
          <tr>
            <td style="width: 33%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">Junfeng Wang</div>
            </td>
            <td style="width: 34%; vertical-align: top;">&#160;</td>
            <td style="width: 33%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 33%; vertical-align: top;">&#160;</td>
            <td style="width: 34%; vertical-align: top;">&#160;</td>
            <td style="width: 33%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">/s/ Christopher Twomey</div>
            </td>
            <td style="width: 34%; vertical-align: top;">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">Director</div>
            </td>
            <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">March 10, 2020</div>
            </td>
          </tr>
          <tr>
            <td style="width: 33%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">Christopher Twomey</div>
            </td>
            <td style="width: 34%; vertical-align: top;">&#160;</td>
            <td style="width: 33%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 33%; vertical-align: top;">&#160;</td>
            <td style="width: 34%; vertical-align: top;">&#160;</td>
            <td style="width: 33%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">/s/ Kristiina Vuori, M.D., Ph.D.</div>
            </td>
            <td style="width: 34%; vertical-align: top;">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">Director</div>
            </td>
            <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">March 10, 2020</div>
            </td>
          </tr>
          <tr>
            <td style="width: 33%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">Kristiina Vuori, M.D., Ph.D.</div>
            </td>
            <td style="width: 34%; vertical-align: top;">&#160;</td>
            <td style="width: 33%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
      <div>
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
    </div>
  </div>
</body>
</html>
[{"type": "S-8", "sequence": "1", "filename": "nt10009730x2_s8.htm", "description": "S-8", "secsgml_size_bytes": 50133}]
{"company-data": {"conformed-name": "Bionano Genomics, Inc", "cik": "0001411690", "assigned-sic": "3826", "irs-number": "261756290", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-237069", "film-number": "20703186"}, "business-address": {"street1": "9540 TOWNE CENTRE DRIVE", "street2": "SUITE 100", "city": "SAN DIEGO", "state": "CA", "zip": "92121", "phone": "(858) 888-7600"}, "mail-address": {"street1": "9540 TOWNE CENTRE DRIVE", "street2": "SUITE 100", "city": "SAN DIEGO", "state": "CA", "zip": "92121"}, "former-company": [{"former-conformed-name": "BioNano Genomics, Inc", "date-changed": "20120703"}, {"former-conformed-name": "BioNanomatrix Inc", "date-changed": "20070906"}]}
As filed with the Securities and Exchange Commission on March 10, 2020
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Bionano Genomics, Inc.
(Exact name of registrant as specified in its charter)
Delaware
26-1756290
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
9540 Towne Centre Drive, Suite 100
San Diego, California
92121
(Address of Principal Executive Offices)
(Zip Code)
Bionano Genomics, Inc. Amended and Restated 2018 Equity Incentive Plan
Bionano Genomics, Inc. 2018 Employee Stock Purchase Plan
(Full titles of the plans)
R. Erik Holmlin, Ph.D.
President and Chief Executive Officer
Bionano Genomics, Inc.
9540 Towne Centre Drive, Suite 100
San Diego, California 92121
(858) 888-7600
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Thomas A. Coll, Esq.
James C. Pennington, Esq.
Cooley LLP
4401 Eastgate Mall
San Diego, California 92121
(858) 550-6000
R. Erik Holmlin, Ph.D.
President and Chief Executive Officer
Bionano Genomics, Inc.
9540 Towne Centre Drive, Suite 100
San Diego, California 92121
(858) 888-7600
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the
      definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☐
Accelerated filer
☐
Non-accelerated filer
☒
Smaller reporting company
☒
Emerging growth company
☒
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
      standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.
☐
CALCULATION OF REGISTRATION FEE
Title of Securities
to be Registered
Amount
to be
Registered
(1)
Proposed
Maximum
Offering Price
Per Share
(2)
Proposed
Maximum
Aggregate
Offering Price
(2)
Amount of
Registration Fee
2018 Equity Incentive Plan
Common Stock, $0.0001 par value per share
1,713,723
(3)
$0.75
$1,285,293
$167
2018 Employee Stock Purchase Plan
Common Stock, $0.0001 par value per share
220,000
(4)
$0.75
$165,000
$22
Total
1,933,723
$1,450,293
$189
(1)
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "
Securities Act
"), this Registration Statement
              shall also cover any additional shares of Common Stock ("
Common Stock
") of Bionano Genomics, Inc. (the "
Registrant
") that
              become issuable under the Registrant's 2018 Equity Incentive Plan (the "
2018 Plan
") or the Registrant's 2018 Employee Stock Purchase Plan (the "
2018 ESPP
") by reason of any stock dividend, stock split, recapitalization or other similar transaction.
(2)
This estimate is made pursuant to Rule 457(h)(1) and Rule 457(c) of the Securities Act solely for purposes of calculating the registration fee. The price per share and aggregate
              offering price are based upon the average of the high and low prices of the Common Stock on March 9, 2020, as reported on the Nasdaq Capital Market.
(3)
Represents shares of Common Stock that were automatically added to the shares authorized for issuance under the 2018 Plan on January 1, 2020 pursuant to an "evergreen" provision
              contained in the 2018 Plan. Pursuant to such provision, on January 1
st
of each year through January 1, 2028, the number of shares authorized for issuance under
              the 2018 Plan will be automatically increased by the lesser of: (a) 5% of the total number of shares of capital stock of the Registrant outstanding on December 31 of the preceding calendar year; or (b) such lesser number of shares of Common
              Stock as the Registrant's board of directors (the "
Board
") may designate prior to the applicable January 1
st
.
(4)
Represents shares of Common Stock that were automatically added to the shares authorized for issuance under the 2018 ESPP on January 1, 2020 pursuant to an "evergreen" provision
              contained in the 2018 ESPP. Pursuant to such provision, on January 1
st
of each year through January 1, 2028, the number of shares authorized for issuance under
              the 2018 ESPP will be automatically increased by a number equal to the lesser of: (a) 1% of the total number of shares of capital stock outstanding on December 31 of the preceding calendar year; (b) 220,000 shares; or (c) such lesser number
              of shares of Common Stock as the Board may designate prior to the applicable January 1
st
.
INCORPORATION OF DOCUMENTS BY REFERENCE
This Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement of the Registrant on
        Form S-8 relating to the same employee benefit plan is effective.
The Registrant previously registered shares of its Common Stock for issuance under the 2018 Plan and 2018 ESPP under Registration Statements on Form S-8 filed with the Securities and Exchange
        Commission (the "
Commission
") on
August 28, 2018 (File No. 333-227073)
and
March 28, 2019 (File No. 333-230589)
. Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the
        contents of the Registration Statements referenced above.
ITEM 8. EXHIBITS.
Exhibit
Number
Description
4.1
(1)
Amended and Restated Certificate of Incorporation of the Registrant.
4.2
(1)
Amended and Restated Bylaws of the Registrant.
4.3
(2)
Form of Common Stock Certificate of the Registrant.
5.1
Opinion of Cooley LLP.
23.1
Consent of Independent Registered Public Accounting Firm.
23.2
Consent of Cooley LLP. Reference is made to Exhibit 5.1.
24.1
Power of Attorney. Reference is made to the signature page hereto.
99.1
(3)
Bionano Genomics, Inc. 2018 Equity Incentive Plan.
99.2
(2)
Forms of Stock Option Grant Notice, Option Agreement and Notice of Exercise under the 2018 Plan.
99.3
(3)
Bionano Genomics, Inc. 2018 Employee Stock Purchase Plan.
(1)
Incorporated by reference to the Registrant's Current Report on Form 8-K, filed with the SEC on August 24, 2018.
(2)
Incorporated by reference to the Registrant's Registration Statement on Form S-1 (File No. 333-225970), as amended.
(3)
Incorporated by reference to the Registrant's Registration Statement on Form S-8 (File No. 333-227073).
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on
        Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on March 10, 2020.
BIONANO GENOMICS, INC.
By:
/s/ R. Erik Holmlin, Ph.D.
R. Erik Holmlin, Ph.D.
President and Chief Executive Officer
POWER OF ATTORNEY
KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints R. Erik Holmlin, Ph.D. as his or her true and lawful attorney-in-fact and agent, with the
        full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with exhibits
        thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be
        done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to
        be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
Signature
Title
Date
/s/ R. Erik Holmlin, Ph.D.
Chief Executive Officer and Director
March 10, 2020
R. Erik Holmlin, Ph.D.
(Principal Executive and Financial Officer)
/s/ Mark Adamchak
Controller
March 10, 2020
Mark Adamchak
(Principal Accounting Officer)
/s/ David L. Barker, Ph.D.
Director
March 10, 2020
David L. Barker, Ph.D.
/s/ Albert A. Luderer, Ph.D.
Director
March 10, 2020
Albert A. Luderer, Ph.D.
/s/ Junfeng Wang
Director
March 10, 2020
Junfeng Wang
/s/ Christopher Twomey
Director
March 10, 2020
Christopher Twomey
/s/ Kristiina Vuori, M.D., Ph.D.
Director
March 10, 2020
Kristiina Vuori, M.D., Ph.D.